sorafenib has been researched along with Chordoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A | 1 |
| Amela, EY; Bertucci, F; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Collard, O; Isambert, N; Italiano, A; Laurence, V; Le Cesne, A; Lebellec, L; Penel, N; Saada-Bouzid, E; Salas, S; Tresch-Bruneel, E | 1 |
| Castinetti, F; Eroukhmanoff, J; Penel, N; Salas, S | 1 |
| Bertucci, F; Blay, JY; Bompas, E; Camoin, L; Clisant, S; Decoupigny, E; Goncalves, A; Laurence, V; Lebellec, L; Mir, O; Penel, N; Toiron, Y; Tresch-Bruneel, E | 1 |
| Anderson, BE; Mackay, D; Svoboda, RM; Welsch, MJ | 1 |
1 trial(s) available for sorafenib and Chordoma
| Article | Year |
|---|---|
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chordoma; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sarcoma; Sorafenib; Survival Rate | 2015 |
4 other study(ies) available for sorafenib and Chordoma
| Article | Year |
|---|---|
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.
Topics: Antineoplastic Agents; Chordoma; Graves Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chordoma; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
Multiple cutaneous metastatic chordomas from the sacrum.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Chordoma; Female; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sacrum; Skin Neoplasms; Sorafenib | 2012 |